companiesCompany
Sobi (Swedish Orphan Biovitrum)
Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).
Overview
Swedish Orphan Biovitrum markets Kepivance (palifermin) for mucositis after high-dose chemotherapy with stem cell support, Doptelet (avatrombopag) for thrombocytopenia, Gamifant (emapalumab) for haemophagocytic lymphohistiocytosis and Zynlonta (loncastuximab tesirine) in Europe under licence from ADC Therapeutics.
Headquarters
Stockholm, SE
Scorecard
All companies#113of 680 companies, score 23
- approved products +6
- modalities +2
- regions +2
- registry trials +13
1 approved, 0 in phase 3, 0 earlier, 0 targets, 44 registry studies. Formula on the scorecards page.
Type
pharma · SOBI.ST
Stage
Public
Website